Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trialZobair M. Younossi, Victor Ankoma‐Sey, Pierre Bédossa et al.|The Lancet|2019Cited by 1.2k
Intestinal Immune Dysregulation Driven by Dysbiosis Promotes Barrier Disruption and Bacterial Translocation in Rats With CirrhosisLeticia Muñoz, Agustı́n Albillos|Hepatology|2018Cited by 130
HIV Coinfection Predicts Failure of Ledipasvir/Sofosbuvir in Treatment-Naïve Noncirrhotic Patients With HCV Genotype 1Juan Berenguer, Juan González‐García, José Luís Calleja et al.|Open Forum Infectious Diseases|2019Cited by 4